Phase 2a clinical trial for ulcerative colitis using adrenomedulli
Phase 2
Completed
- Conditions
- ulcerative colitis
- Registration Number
- JPRN-jRCT2080225159
- Lead Sponsor
- niversity of Miyazaki
- Brief Summary
Despite the limited number of patients in this double-blind randomized trial, we observed the successful complete remission at 8 weeks in patients with steroid-resistant UC receiving a high dose of AM. Hence, AM could serve as candidate potent therapeutic agent for complete remission in refractory UC.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 28
Inclusion Criteria
patients with steroid-resistant ulcerative colitis
Exclusion Criteria
Patient using biologics
Patient with fulminant ulcerative colitis (UC)
Patient need early operation for UC
Patient with precancerous lesion(s) in the colon
Patient with active infection
Patient with severe complication(s)
Patient with malignancy or past history of malignancy
Pregnant woman
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method